Clin Osteol 2024; 29(1-2): 20-24

Treatment by romosozumab in secondary osteoporosis: a review of the literatureReview articles

Brunerová Ludmila
Interní klinika 3. LF UK a FNKV, Praha

Osteoporosis represents the most common metabolic bone disease, which affects every third woman and every fifth man worldwide. Low-trauma fractures represent the most serious complications of osteoporosis, responsible for significant morbidity, mortality and increased economical costs. Therapy of osteoporosis is based on three pillars -⁠ lifestyle changes, suplementation of vitamin D and calcium and specific antiosteoporotic treatment, which is able to decrease the fracture risk in a half. Romosozumab, a humanized monoclonal antibody against sclerostin has been the most recent anabolic treatment introduced to the Czech market. I tis indicated and reimbursed in postmenopausal women with densitometry osteoporosis and with history of low-trauma fracture, who did not experienced myocardial infarction or stroke. In the following text, original data from studies, identified in PubMed and Medline Plus based on combinations of key words, focusing on the efficacy of romosozumab in specific clinical settings of secondary osteoporosis, is presented.

Keywords: romosozumab; secondary osteoporosis

Published: June 11, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brunerová L. Treatment by romosozumab in secondary osteoporosis: a review of the literature. Clinical Osteology. 2024;29(1-2):20-24.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kanis JA, Johnell O, Oden A et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11(8): 669-674. Dostupné z DOI: <http://dx.doi.org/10.1007/s001980070064>. Go to original source...
    2. Riggs BL, Melton LJ. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983; 75(6): 899-901. Dostupné z DOI: <http://dx.doi.org/10.1016/0002-9343(83)90860-4>. Go to original source...
    3. Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 2015; 173(3): R131-R151. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-15-0118>.. Go to original source...
    4. Palička V, Rosa J, Pikner R et al. Doporučené diagnostické a terapeutické postupy pro praktické lékaře -⁠ Osteoporóza. Novelizace 2023. Dostupné z WWW: <https://smos.cz/wp-content/uploads/2023/12/doporucene_postupy_osteoporoza_2023.pdf>.
    5. Brunerová L. Romosozumab. Zaostřeno. Remedia 2024; 34 : 1-8.
    6. Cosman F, Crittenden DB, Adachi JD et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375(16): 1532-1543. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607948>. Go to original source...
    7. Saag KG, Petersen J, Brandi ML et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377(15): 1417-1427. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1708322>. Go to original source...
    8. Langdahl BL, Libanati C, Crittenden DB et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 2017; 390(10102): 1585-1594. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(17)31613-6>. Go to original source...
    9. Lewiecki EM, Blicharski T, Goemaere S et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab 2018; 103(9): 3183-3193. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2017-02163>. Go to original source...
    10. Miller PD, Adachi JD, Albergaria BH et al. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Miner Res 2022; 37(8): 1437-1445. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.4563>. Go to original source...
    11. Sato M, Inaba M, Yamada S et al. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 2021; 39(6): 1082-1090. Dostupné z DOI: <http://dx.doi.org/10.1007/s00774-021-01253-y>. Go to original source...
    12. Ogata M, Ushimaru S, Fujishima R et al. Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist. Bone Rep 2022; 17 : 101639. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bonr.2022.101639>. Go to original source...
    13. Hsu CP, Maddox J, Block G et al. Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab. J Clin Pharmacol 2022; 62(9): 1132-1141. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.2050>. Go to original source...
    14. Mochizuki T, Yano K, Ikari K et al. Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. Osteoporos Sarcopenia 2021; 7(3): 110-114. Dostupné z DOI: <http://dx.doi.org/10.1016/j.afos.2021.08.001>. Go to original source...
    15. Mochizuki T, Yano K, Ikari K et al. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study. Mod Rheumatol 2023; 33(3): 490-495. Dostupné z DOI: <http://dx.doi.org/10.1093/mr/roac059>. Go to original source...
    16. Ebina K, Nagayama Y, Kashii M et al. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study. Osteoporos Int 2024; 35(5): 841-849. Dostupné z DOI: <https://doi.org/10.1007/s00198-024-07019-2>. Go to original source...
    17. Kurose R, Wakai Y. Efficacy of romosozumab for the treatment of osteoporosis in patients with rheumatoid arthritis in comparison with glucocorticoids therapy. Clin Rheumatol 2023; 35(3): 177-188. Dostupné z DOI: <https://doi.org/10.14961/cra.35.177>.
    18. Kobayakawa T, Miyazaki A, Kanayama Y et al. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 2023; 33(1): 96-103. Dostupné z DOI: <https://doi.org/10.1093/mr/roac014>. Go to original source...
    19. Mok CC, MD, Ma WH, Chan KL et al. Romosozumab versus denosumab in high-risk patients with glucocorticoid-induced osteoporosis: a pilot randomized controlled trial. Abstract OP0246. European Alliance of Associations for Rheumatology (EULAR) 2023 Annual Meeting. Annals of the Rheumatic Diseases 2023; 82(Suppl 1):164.1-164 Go to original source...
    20. Kawazoe M, Kaneko K, Masuoka S et al. Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study. ACR Convergence 2023. Dostupné z WWW: <https://acrabstracts.org/abstract/efficacy-of-romosozumab-for-glucocorticoid-induced-osteoporosis-in-patients-with-rheumatic-diseases-a-prospective-study/>.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.